BGM

BGM Group Ltd. Class A Ordinary Shares (BGM)

Stock · NASDAQ · Health Care

$0.328as of 8/28/2026

Active signals

BOLL Breakout94.0%
High Beta42.4%
Support level
$0.28475
Industry
Biotechnology: Pharmaceutical Preparations

About BGM

BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments. It offers oxytetracycline products, including Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetra…

Sector
Health Care
Industry
Biotechnology: Pharmaceutical Preparations

Fundamentals

1-day range
$0.2721$0.33
Market cap
$118.62M
P/E (trailing)
P/E (forward)
EPS (trailing)
$-0.13
Dividend yield
Beta
1.87
Avg. volume
413.9K
Ex-dividend date
February 27, 2023
Dividend pay date
March 6, 2023
52-week range
$0.2287$11.8
Next earnings: March 16, 2026

BGM Group Ltd. Class A Ordinary Shares Competitors

Chosen by industry and closest market cap.

  • BGM
    BGM Group Ltd. Class A Ordinary Shares
    $0.3251
    ▲ 11.34%
    Market cap $118.62MP/E
    $0.2287$11.8
  • PMN
    ProMIS Neurosciences Inc. Common Shares (ON)
    $13.79
    ▼ 1.43%
    Market cap $119.54MP/E
    $6.27$27.4
  • GNLX
    Genelux Corporation Common Stock
    $2.66
    ▼ 7.64%
    Market cap $121.07MP/E
    $2.29$8.54
  • IFRX
    InflaRx N.V. Common Stock
    $2.22
    ▼ 2.20%
    Market cap $124.34MP/E
    $0.7984$2.95
  • NRXP
    NRX Pharmaceuticals Inc. Common Stock
    $3.54
    ▼ 2.21%
    Market cap $111.95MP/E
  • PLYX
    Polaryx Therapeutics Inc. Common Stock
    $2.07
    ▼ 2.13%
    Market cap $110.66MP/E
    $1.86$48.91
  • SPRB
    Spruce Biosciences Inc. Common Stock
    $60.05
    ▼ 5.13%
    Market cap $127.76MP/E
    $7$240

P/E shows — for peers not currently carrying a live signal of their own.

See the full, filterable feed with live charts on the MarketWall dashboard.

We use analytics to understand how market-wall is used. No personal data is sold.